UPDATE: Amedisys (AMED) Reports In-Line EPS, Revenue Tops Views; CFO to Retire
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Mizuho Securities Downgrades Amedisys (AMED) Neutral, PT Cut to $55
August 3, 2016 7:06 AM EDTMizuho Securities downgraded Amedisys (NASDAQ: AMED) from Buy to Neutral and cut the price target to $55.00 (from $57.00), following the company's 2Q earnings report. Management pointed out that it had underestimated the HCHB disruption costs previously and is working to correct that. As a... More
